menu
    • menu
    [{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ AVROBIO","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ AVROBIO"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.13,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ TAS Partners"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Relaxin-2 protein, human","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"TX000045","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Avrobio","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ Avrobio"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ TAS Partners"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TX000045","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tectonic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TX000045","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tectonic Therapeutic \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tectonic Therapeutic

    Menu

    Tectonic Therapeutic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TX000045

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tectonic Shows Favorable Phase 1a Results For Lead Program TX45

                            Details : TX000045 (TX45) is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF).

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 19, 2024

                            Lead Product(s) : TX000045

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TX000045

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

                            Details : TX000045 (TX45) is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF).

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 30, 2024

                            Lead Product(s) : TX000045

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Avrobio

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Tectonic Therapeutic Closes Merger with AVROBIO and Private Placement of $130.7 Million

                            Details : Through the merger with AVROBIO, Tectonic will be focused on advancing a pipeline, including TX45 (TX000045), which is being evaluated for Pulmonary Hypertension in patients with Heart Failure.

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 20, 2024

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Avrobio

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : TAS Partners

                            Deal Size : $180.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Tectonic Therapeutic Closes Merger with AVROBIO and Private Placement of $130.7 Million

                            Details : The proceeds will support the Tectonic to focus on advancing a pipeline, including the program, TX45 (TX000045), which is being evaluated for Pulmonary Hypertension in patients with Heart Failure.

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 20, 2024

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : TAS Partners

                            Deal Size : $180.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tectonic Initiates Phase 1B for TX45 in Group 2 HFpEF Patients

                            Details : TX45 is an investigational long-acting relaxin-Fc fusion molecule. It is being evaluated for group 2 pulmonary hypertension secondary to heart failure with preserved ejection fraction.

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : Relaxin-2 protein, human

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Avrobio

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            AVROBIO and Tectonic Therapeutic Announce Merger

                            Details : The combined company will focus on advancing Tectonic’s pipeline, including TX45 (TX000045), a Fc-relaxin fusion protein targeting the RXFP1 receptor and a potential best-in-class agent.

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 30, 2024

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Avrobio

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : TAS Partners

                            Deal Size : $130.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            AVROBIO and Tectonic Therapeutic Announce Merger

                            Details : The proceeds will be used to advance Tectonic’s pipeline, including TX45 (TX000045), a Fc-relaxin fusion protein targeting the RXFP1 receptor and a potential best-in-class agent.

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 30, 2024

                            Lead Product(s) : TX000045

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : TAS Partners

                            Deal Size : $130.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Tectonic Therapeutic

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TX000045

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic

                            Details : TX45 (TX000045), a Fc-relaxin fusion protein targeting the RXFP1 receptor and a potential best-in-class agent, resulting from protein engineering efforts to overcome the human hormone’s biophysical property limitations.

                            Brand Name : TX45

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 28, 2023

                            Lead Product(s) : TX000045

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth